Engineering a Camelid Antibody Fragment That Binds to the Active Site of Human Lysozyme and Inhibits Its Conversion into Amyloid Fibrils-Reference-Cited by-同舟云学术

Engineering a Camelid Antibody Fragment That Binds to the Active Site of Human Lysozyme and Inhibits Its Conversion into Amyloid Fibrils

Published:2008-09-25 Issue:42 Volume:47 Page:11041-11054
ISSN:0006-2960
Container-title:Biochemistry
language:en
Short-container-title:Biochemistry

Author:

Chan Pak-Ho¹,Pardon Els¹,Menzer Linda¹,De Genst Erwin¹,Kumita Janet R.¹,Christodoulou John¹,Saerens Dirk¹,Brans Alain¹,Bouillenne Fabrice¹,Archer David B.¹,Robinson Carol V.¹,Muyldermans Serge¹,Matagne André¹,Redfield Christina¹,Wyns Lode¹,Dobson Christopher M.¹,Dumoulin Mireille¹

Affiliation:

1. Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, U.K., Laboratorium voor Ultrastructuur, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium, Department of Molecular and Cellular Interactions, VIB, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium, Laboratoire d’Enzymologie, Centre d’Ingénierie des Protéines, Institut de Chimie B6, Université de Liège, B-4000 Liège (Sart Tilman), Belgium, Laboratorium voor Cellulaire en Moleculaire Immunologie...

Publisher

American Chemical Society (ACS)

Subject

Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/bi8005797

Reference48 articles.

1. Human lysozyme gene mutations cause hereditary systemic amyloidosis

2. ALys amyloidosis caused by compound heterozygosity in Exon 2 (Thr70Asn) and Exon 4 (Trp112Arg) of the lysozyme gene

3. Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family

4. A novel lysozyme mutation Phe57Ile associated with hereditary renal amyloidosis

5. Lysozyme

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A selection and optimization strategy for single-domain antibodies targeting the PHF6 linear peptide within the tau intrinsically disordered protein;Journal of Biological Chemistry;2024-04

2. Strategy of selection and optimization of single domain antibodies targeting the PHF6 linear peptide within the Tau intrinsically disordered protein;2023-07-19

3. CRISPRi-microfluidics screening enables genome-scale target identification for high-titer protein production and secretion;Metabolic Engineering;2023-01

4. The current state of amyloidosis therapeutics and the potential role of fluorine in their treatment;Biochimie;2022-11

5. Development of nanobodies as theranostic agents against CMY-2-like class C β-lactamases;2022-07-03